StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners increased their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Trading Up 6.4 %

Shares of NASDAQ:TNXP opened at $0.16 on Tuesday. The company’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $4.07. Tonix Pharmaceuticals has a one year low of $0.13 and a one year high of $29.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The stock has a market capitalization of $476,864.20, a PE ratio of 0.00 and a beta of 2.09.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. On average, equities analysts forecast that Tonix Pharmaceuticals will post -39 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the period. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.